WO2001007005A1 - Utilisation d'une fraction de proteine de la graine de la plante vigna trilobata dans une composition cosmetique ou dermopharmaceutique - Google Patents

Utilisation d'une fraction de proteine de la graine de la plante vigna trilobata dans une composition cosmetique ou dermopharmaceutique Download PDF

Info

Publication number
WO2001007005A1
WO2001007005A1 PCT/EP2000/007007 EP0007007W WO0107005A1 WO 2001007005 A1 WO2001007005 A1 WO 2001007005A1 EP 0007007 W EP0007007 W EP 0007007W WO 0107005 A1 WO0107005 A1 WO 0107005A1
Authority
WO
WIPO (PCT)
Prior art keywords
extracted
protein fraction
cosmetic
grains
active ingredient
Prior art date
Application number
PCT/EP2000/007007
Other languages
German (de)
English (en)
Inventor
Gilles Pauly
Philippe Moser
Véronique Gillon
Original Assignee
Cognis France, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognis France, S.A. filed Critical Cognis France, S.A.
Priority to AU62765/00A priority Critical patent/AU6276500A/en
Publication of WO2001007005A1 publication Critical patent/WO2001007005A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin

Definitions

  • the present invention relates to the field of cosmetics and dermopharmacology and its object is to use at least one protein extract of the grain of the Vigna trilobata plant, and a cosmetic product containing such an extract.
  • Phaseolus trilobus Ait This plant is mentioned in various traditional articles under the name Phaseolus trilobus Ait (see in particular GC Toms: J. Pharmacy & Pharmacol, Volume 30, 79 P, 1978) and its chemical composition and nutritional potential have been described by S. Siddhuraju, K. Vijayakumari and K. Janardanan ("Nutrional and chemical evaluation of raw seeds of the tribal pulse Vigna trilobata” (L.) Verdc. International Journal of food sciences and nutrition (1992), 43, n ° 2, 97-103).
  • the chemical composition (g / 100 g of flour obtained from grains) of Vigna trilobata grains is as follows:
  • the mineral composition of these grains is rich in potassium (1397 mg / 100 g flour), calcium (464 mg / 100 g flour), magnesium (291 mg / 100 g flour).
  • the amino acid composition indicates that the sulfur-containing amino acids (cystine and methionine), threonine and isoleucine can be found in limited quantities, whereas valine, leucine, tyrosine, phenylalanine and lysine are present in sufficient quantities.
  • the globulin fraction of the proteins is said to have a blood-clotting activity for groups A, B, O.
  • the inventors have found in an unexpected and astonishing way that the protein extracts of the Vigna trilobata grains, in addition to their nutritious properties, also in topical application on the skin, the epithelial appendages and the mucous membranes, have special biological effects and have a very good tolerance and that the use as an active ingredient, alone or in conjunction with at least one other active ingredient, of at least one soluble protein fraction extracted from Vigna trilobata in a composition or a cosmetic or dermopharmaceutical product enables specific, identifiable and quantitatively measurable properties when used locally on the Skin, the epithelial appendages and / or the mucous membranes.
  • the preparation of the proteins is carried out by the conventional techniques for extracting vegetable proteins, the preparation of concentrates or protein isolates or by purification (ultrafiltration, ion exchange chromatography, affinity chromatography, precipitation, adsorption), which are known to the person skilled in the art.
  • the extraction with water or an aqueous solution is preferably carried out at a given pH, possibly by an ultrasound generator.
  • a given pH possibly by an ultrasound generator.
  • various processes for obtaining and preparing protein extracts from two different, divided quantities of Vigna trilobata grains of Indian origin are described below.
  • the protein content (N x 6.25) of the two grains, A and B, is 20.75% and 20.92%.
  • the pH of the solution is adjusted to the pH of 7.5 using sodium hydroxide solution.
  • the extraction is carried out for 2 hours at room temperature by keeping the extraction pH at 7.5.
  • the beige substance floating on the surface is collected and then filtered to 0.5 ⁇ m.
  • the extract can be dewatered by conventional techniques such as atomization, freeze drying or the like. After atomization, the powder-like product obtained has a protein content (N x 6.25) of 42.5% (extract 1a).
  • a second extract, prepared under the same conditions, from a different amount of grains makes it possible to obtain an extract that contains a protein content (N x 6.25) of 46.4% (extract 1 b).
  • the pH of the solution is adjusted to pH 4.5 with sulfuric acid and left for 30 minutes with stirring.
  • the solution is then centrifuged for 15 minutes at 5000 g: the precipitate and the matter floating on the surface are collected.
  • the precipitate is placed as a solution in a water volume that corresponds to 20% of the volume before the precipitation.
  • the pH of the solution is adjusted with NaOH until it stabilizes at 7.5.
  • the solution is centrifuged again to separate out the insoluble substances. 600 ml of a 3.5% dry extract solution are obtained, which is dewatered by atomization.
  • the powder-like product obtained has a protein content (N x 6.25) of 80.6% (extract 2a).
  • a second extract is prepared under the same conditions from a different amount of grains, it enables an extract to be obtained which has a protein content (N x 6.25) of 80.7% (extract 2b).
  • the powder obtained has a protein content of 15% to 20% and an inhibitory activity of trypsin, which was determined by the Kakade technique with 8.4 TUl / mg to 13.3 TUl / mg.
  • fractions can therefore serve as the basis for the purification of protease inhibitors (with regard to the use of an extract which consists of a fraction enriched with protease inhibitors).
  • retentate R2 150 ml of distilled water are added to the retentate and the solution is concentrated again to 50 ml (retentate R2).
  • Retentate R2 is dehydrated by freeze-drying: a fraction with an 80.7% protein content (N x 6.25) is obtained.
  • a protein concentrate is prepared from 350 g of grains according to Example 2, the initial extraction being carried out in a flour / solvent ratio of 1/15.
  • the precipitate is dissolved at pH 7.5 in 1.5 liters of distilled water.
  • the hydrolysis is carried out for 2 hours at an optimized temperature and pH of the enzyme used, the optimized values are known to the person skilled in the art.
  • the enzyme is inactivated by heating to 100 ° C for at least 10 minutes.
  • the solution After cooling to room temperature, the solution is centrifuged and then filtered to 0.22 ⁇ m.
  • the powder obtained has a protein content of 70.75% (extract 3a).
  • fraction F1 with a very high molecular weight (over 500,000 Da and close to 1,000,000 Da according to the calibration of the column), - a fraction F2 whose molecular weight is between 250,000 Da and 300,000 Da (295,000 Da),
  • the extracts obtained by the process examples described can be used directly in liquid form or after drying using the conventional drainage techniques (atomization, freeze-drying).
  • the protein fractions obtained can be used either in their original form, without changing the structures or in the form of one or more natural compounds of at least two or all extracted fractions of different visible molecular weights, which correspond to the different chromatogram peaks shown in the accompanying drawings and are found naturally in the grains (total or partial protein extract) or in isolated form.
  • the protein fractions can be used in compositions in their form modified or functionalized by any of the following procedures:
  • Vigna trilobata proteins as a fermentation substrate by various microorganisms, such as yeast (Saccharomyces - yeast), mold (Aspergillus), bacteria, (bacillus and the like);
  • extracts or releasable protein fractions according to the invention can also be added to or connected to any other applicable cosmetic vector, for example film-forming agents, liposomes, cyclodextrins, micelles, macro, micro and nanoparticles, as well as macro, micro and nanocapsules or they can be absorbed or transplanted onto organic polymers or mineral carriers.
  • Vigna trilobata protein extracts were determined and measured by tests known to those skilled in the art, the results of which are shown below:
  • Human fibroblasts are vaccinated in an optimum medium (with SVF) and incubated for 24 hours at 37 ° C.
  • the growth medium is then replaced by a sub-optimal medium (without SVF) containing various concentrations of extracts as described in the invention. After a 3-day incubation, the growth was evaluated by counting the adherent cells by an automatic particle counter and by dosing the intracellular ATP content.
  • results are calculated in relation to a test measurement scale and then specified in a percentage in relation to the untreated control agent and finally created as an average with SEM (error type of the average).
  • Figure 4 show that the extracts 1a and 2a at doses between 0.003% and 0.03% (w / v - weight-volume), the number of cells and the ATP content in the human Fibroblasts in in vitro growth increase significantly ( Figures 4A and 4B each represent the cells counted after three days and the ATP content after three days for different concentrations with 1a and 2a extracts).
  • the test is done on fibroblasts according to the same protocol as growth, with an incubation period of 72 hours.
  • ATP adenosine triphosphate
  • GSH glutathione
  • FIGS. 5A and 5B each represent the protein content and the GSH content, which were measured after three days for different concentrations with 2a, 2b and 3 extracts.
  • FIGS. 5A and 5B indicate that the protein extracts from Vigna trilobata according to Example 2 at 0.05% (w / v) the content of the proteins and of the glutathione in the human fibroblasts in vitro - Increase survival significantly.
  • the extract according to Example 3 at 0.01% w / v) also slightly increases the protein and glutathione content in human fibroblasts in in vitro survival.
  • Proteins and glutathione) by human fibroblasts have what clearly indicates an energizing, stimulating and "anti-aging" activity of these extracts.
  • the contraction of the collagen network results from a series of biological functions that are triggered by fibroblasts, it enables scarring of wounds in vivo and also the maintenance of a good dermis.
  • contracting the collagen network in vitro is a good model for evaluating the ability of a substance to activate scarring or to reduce the contracting of an old person's dermis.
  • Figures 6 and 7 of the drawings in the appendix each show the surface of the rods in cm 2 and the separated GAG contents (in pericellular staining intensity) on the 14th day of incubation with different concentrations of extracts 2a and 2b.
  • the collagen network does not contract in a culture medium without calf fetus serum (SVF).
  • Apoptosis is a biological, active process used by living organisms to remove certain cells from their tissues by autolysis, especially the destruction of proteins and nuclear ADN into small fragments that are salted out into the cytoplasm.
  • Apoptosis can also be induced by oxidative stress (UV-R, inflammation), by lack of growth factors or by toxic substances (pollutants, genotoxic substances ).
  • the principle of the test is to demonstrate the ability of the extracts according to the invention to reduce the level of apoptosis induced in a culture medium with cells lacking growth factors.
  • the human keratinocytes are vaccinated in a complete culture medium (with calf fetus serum or SVF), which contains an ADN marker: bromodeoxy uridine or BrdU.
  • SVF complete culture medium
  • the cells then receive a culture medium without serum, which contains different concentrations of the substances to be tested and which are incubated at 37 ° C. for 1 or 2 days. After the incubation, the cells are recovered by trypsinization and then analyzed.
  • the cells are lysed and the content of the apoptotic cells is quantified by an ELISA test which reveals BrdU which has been incorporated into the cytoplasmic ADN fragments.
  • FIGS. 8A and 8D represent the cell count and the apoptosis content (content of the ADN fragments) for the extracts 1a, 1b, 2a and 2b for different concentrations.
  • the extracts according to the invention have shown considerable abilities to reduce the level of apoptosis induced in a culture medium of human cells which lack a growth factor, which explains the high abilities of these extracts the aging of tissue by a "growth factor”. like "effect (type growth factor). 5) PROOF OF THE ABILITIES OF CYTAL PROTECTION AGAINST OXYDATIVE STRESS
  • UV-A This in vitro test evaluates the capabilities of cytophotos protection of human fibroblasts against UV-A.
  • the UV-A are selected as the study model because they penetrate into the dermis and induce an oxidative stress in the skin, which in particular reveals lipoperoxidation of the cytoplasmic membrane and a decrease in the activity of numerous enzymes, including that of catalase.
  • Fibroblasts are vaccinated in a nutrient medium which is defined with calf fetus serum (SVF).
  • Vigna trilobata extracts according to the invention were added 2 to 3 days after inoculation.
  • the nutrient medium is replaced by a saline solution and the fibroblasts are irradiated with a UV-A dose (3 to 15 J / cm 2 ).
  • the MDA content (malonaldialdehyde) is dosed in a salt solution floating on the surface and the content of the proteins, Reduced glutathione (GSH) and active catalase are measured in the fibroblasts.
  • GSH Reduced glutathione
  • MDA is dosed by the reaction to thiobarbiturate acid and the proteins according to the so-called Bradford method, whereas GSH is dosed by a fluorescent probe.
  • the content of the active catalase is dosed by a spectrophotometric method and the activity of the catalase is based on the protein content measured in the fibroblasts.
  • FIGS. 9A and 9B represent the measured contents of MDA, the proteins, of GSH and the catalase, which represents the relative cytophoto protective activity (% in relation to the control means) of the extracts 1a and 2a.
  • Vigna trilobata extracts have a high ability to reduce the harmful effects of oxidative stress on the skin.
  • UV-B was chosen as an inducer because it causes cutaneous inflammation (erythema, edema) through the activation of enzymes such as phospholipase A2 (PLA2), which releases arachidonic acid (unsaturated fatty acid), which is present in the biological membranes is.
  • PHA2 phospholipase A2
  • arachidonic acid unsaturated fatty acid
  • this leads to damage to the membrane and the synthesis of the inflammatory transmission agents (mediator), because the arachidonic acid is converted under the action of the so-called “cyclo-oxygenase” enzymes into prostaglandins (PG), such as PGE2.
  • PG prostaglandins
  • the PGE2 are released outside the cell and they will induce erythema and edema by fixation on specific recipients.
  • the UV-B induces lesions of the ADN into the keratinocytes, which can be direct, such as thymidine dimers or indirectly, as in the case of apoptosis (which was initiated by the UV) where the ADN is fragmented and then in the cytoplasm in the form small fragments is salted out.
  • UV-B All effects of UV-B were evaluated on in vitro cultures of keratinocytes.
  • FIGS 10A and 10B of the accompanying drawings illustrate the relative activities related to the anti-inflammatory properties of extracts 1a, 1b, 2a and 2b.
  • Vigna trilobata extracts according to the invention therefore have high abilities to reduce lesions introduced on the biological membranes and on the ADN by UV-B and to reduce the inflammatory process induced by the UV-B on the human keratinocytes.
  • the experiment consists of a sensory evaluation of the effects produced after standardized use of capsaizine to 0.075% in vivo on humans: irritation, burning, pain and erythema.
  • the test is carried out by an expert assistant under standardized conditions with regard to temperature and relative humidity on a test person who is very sensitive to capsaicine on the face; both persons have been trained to describe the effects observed during the test.
  • Extract 2a which was introduced at 1.5% in an H / E emulsion, is applied to a cutaneous zone limited to the cheek.
  • a cream dosed with 0.075% capsaizine was also applied 30 minutes after drying.
  • the test was conducted against a placebo (H / E emulsion only) and against a control agent (not pre-treated skin to which only capsaicine cream is applied).
  • the 2a extract improves the parameters for pain and irritation by 83% (25% for placebo) and the parameters for erythema by 22% (14% for placebo), making its soothing, anti-irritant and anti-sensitive skin -Effect is proven.
  • the experiment consists of measuring the displacement of the skin according to a sinusoidal, constant force that is exerted parallel to its surface.
  • the measuring operations take place according to a device of the type to which the French patent application N ° 98 12125 refers to the name of the applicant.
  • the processing of the signals of the force and extension by means of a hysteresis ellipse enables the calculation of the dynamic effort or DSR (Dynamic Spring Salary).
  • DSR Dynamic Spring Salary
  • the application of a firming product on the surface of the skin manifests itself by an increase in DSR, a consequence with constant strength, a decrease in the expansion of the skin during stress.
  • the equipment is completely computer controlled. The tests are carried out under standardized conditions with regard to temperature and relative humidity.
  • a patch with super glue is stuck on a cutaneous zone on the back of the test person's hand.
  • Five horizontal extensiometer measurements are then made on the untreated control agent skin.
  • the placebo Carrier applied. After drying for 5 minutes, five measuring processes are used to check the effect of the carrier.
  • the skin is then treated again with the active ingredient, the firming effect of which is measured by five last measuring processes after waiting for ⁇ minutes. The average of the five measurements is determined during each stage. The final results are produced as a percentage of the change in DSR between the one by the placebo carrier (water) and the activity of the active ingredient.
  • the 2a extract which was tested on a healthy, female test person in an aqueous solution at a 1.5% concentration, increased the DSR by 76%, thereby demonstrating its firming cutaneous effect.
  • the experiment consists in applying a constant force to the skin using a sliding shoe that is rotated at a controlled speed and pressure. The moment of friction is measured. It enables the calculation of the coefficient of friction of the sliding shoe on the skin.
  • the coefficient of friction depends on the condition of the skin surface, especially its moisture and softness. The more hydrated and softer the skin is to be touched, the more the coefficient of friction increases.
  • the equipment is completely computer controlled. The tests are carried out under standardized conditions with regard to temperature and relative humidity.
  • a cutaneous, 9 cm 2 zone on the inner surface of the test person's forearm is used to perform a friometric measurement on the skin without treatment (TO). Then the active ingredient is applied. After drying for 15 minutes, a friction measurement is used to check the effectiveness of the active ingredient (T15). At the same time, an adjacent cutaneous control agent zone is measured under the same conditions. The result is in the percentage difference of Change between TO and T15 of the treated zone in relation to the control agent zone indicated.
  • the 2a extract tested on a healthy female test subject as an aqueous solution with a 1.5% concentration increases the coefficient of friction by 20.9%, which proves its effectiveness in improving cutaneous softness and moisture.
  • the object of the present invention is also a cosmetic or dermopharmaceutical composition for topical application to the skin, the epithelial appendages and / or the mucous membranes, which as an active ingredient alone or in combination with at least one other active ingredient, contains at least one protein fraction which extracted from Vigna trilobata grains.
  • This cosmetic composition as a single active ingredient or combined with at least one other active ingredient, can contain at least one extract of the aforementioned type which is used to produce at least one of the particular biological effects which have been described above, or even several of these effects as a combination.
  • the cosmetic or dermopharmaceutical composition according to the invention may advantageously contain between 0.001% and 50% by weight protein fraction (s) extracted from Vigna trilobata grains (the extracts were obtained by one of the aforementioned methods), which may be can be incorporated into suitable cosmetic vectors such as liposomes, macro, micro and nanocapsules, macro, micro and nanoparticles and other analog and known forms.
  • suitable cosmetic vectors such as liposomes, macro, micro and nanocapsules, macro, micro and nanoparticles and other analog and known forms.
  • the aforementioned extracts can not only be used for skin care and hygiene applications (products for the face and body, day or night cosmetics, sunscreens, strengthening, regenerating products, anti-wrinkle cosmetics, slimming products, agents against aging processes), but also in the field of epithelial appendage care and hygiene in the form of various finished products, such as lotions or shampoos, creams, foaming agents, soaps, sticks, gels, hydrogels, sprays, emulsions, Protective agents, repairing, softening, film-forming and photo-protective agents; Perm and hair dye products.
  • a cosmetic product in the form of a cream for nourishing, firming, refreshing and energizing, which is intended to combat cutaneous aging, the contraction of the dermis and the loss of elasticity of the skin, can consist of the following phases:
  • the preparation process of the aforementioned cream essentially consists of heating the fat phase to 80 ° C, also heating the aqueous phase to 80 ° C and dissolving Elestab 4112 therein, separately preparing the mother liquor of the Vigna extract, the fat phase in place the aqueous phase under turbine stirring, then add the mother liquor of the Vigna extract at about 50 ° C and finally continue stirring until cooling.
  • a cosmetic product in the form of a cream for softening, biofilming, relieving, scarring, which is particularly intended to combat aggression by sun exposure and pollution, and to care for sensitive skin types (anti-irritation, to reduce inflammation) can be from the following Phases exist:
  • Vigna proteins according to Example 2 (2a extract) 5.00 distilled water 9.00
  • the preparation process of the aforementioned cream consists mainly of heating the fat phase to 80 ° C, also heating the aqueous phase to 80 ° C, dissolving Elestab 388 and PVP therein, the fat phase into the aqueous phase with turbine stirring at 80 ° P pour, then gradually cool while stirring, then add the mother dispersion of the Vigna extract at about 50 ° C and finally continue stirring until it cools down.
  • a cosmetic product in the form of a conditioning, non-rinsed and biofilm-forming hair tonic which is particularly intended to make combing of the epithelial appendages easier and to improve its softness and suppleness, can have the following composition: Vigna proteins according to Example 1 (1a extract) 2.00 distilled water 9.50
  • the method of preparation of the non-rinsed lotion consists mainly in dissolving Elestab 305 and hydroxyethyl cellulose in water heated to about 50 ° C, in the distribution of the perfume and Crempphors RH 410 therein, then in the cooling of the mixture to room temperature, then in Dissolution of the Vigna extract in it and finally in the execution of a filtering process.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention vise à utiliser au moins une fraction de protéine soluble, extraite de la graine de la plante Vigna trilobata, comme principe actif dans une composition cosmétique ou dermopharmaceutique à appliquer localement sur la peau, les appendices épithéliaux ou les muqueuses.
PCT/EP2000/007007 1999-07-26 2000-07-21 Utilisation d'une fraction de proteine de la graine de la plante vigna trilobata dans une composition cosmetique ou dermopharmaceutique WO2001007005A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62765/00A AU6276500A (en) 1999-07-26 2000-07-21 Use of a protein fraction of the seed of the vigna trilobata-plant in a cosmeticor dermopharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/09766 1999-07-26
FR9909766A FR2796839B1 (fr) 1999-07-26 1999-07-26 Utilisation d'une fraction proteique de la graine de la plante vigna trilobata dans une composition cosmetique ou dermopharmaceutique

Publications (1)

Publication Number Publication Date
WO2001007005A1 true WO2001007005A1 (fr) 2001-02-01

Family

ID=9548600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007007 WO2001007005A1 (fr) 1999-07-26 2000-07-21 Utilisation d'une fraction de proteine de la graine de la plante vigna trilobata dans une composition cosmetique ou dermopharmaceutique

Country Status (3)

Country Link
AU (1) AU6276500A (fr)
FR (1) FR2796839B1 (fr)
WO (1) WO2001007005A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101421230B (zh) * 2001-11-16 2011-04-13 辛根塔参与股份公司 新颖的苯基-炔丙基醚衍生物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1310261A1 (fr) 2001-11-09 2003-05-14 Cognis France S.A. Utilisation d'un extrait de Vigna aconitifolia dans une composition cosmétique et/ou dermopharmaceutique
DE10206353A1 (de) * 2002-02-14 2003-08-28 Cognis Deutschland Gmbh Verwendung von niedermolekularen Proteinhydralysaten
EP2216074A1 (fr) * 2009-02-07 2010-08-11 Cognis IP Management GmbH Extrait de dolichos biflorus à utiliser dans un traitement cosmétique de la peau
US20140106009A1 (en) * 2010-11-03 2014-04-17 Cimtech Pty Limited Methods and compositions for maintaining and improving the health of skin
EP3166589B1 (fr) 2014-07-08 2020-04-08 Henkel AG & Co. KGaA Compositions cosmetiques comprenant des proteines de légumineuses du genre pisum, et qui ne comprennent pas des halogénures et/ou hydroxyhalogénures d'aluminium et/ou de zirconium
FR3076460B1 (fr) * 2018-01-09 2020-11-13 Basf Beauty Care Solutions France Sas Utilisation cosmetique d'un extrait proteique des graines de moringa oleifera

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322839A (en) * 1991-09-13 1994-06-21 Pentapharm Ag Protein fraction for cosmetic and dermatology care of the skin
JPH0853360A (ja) * 1994-06-10 1996-02-27 Suntory Ltd ヒスタミン遊離抑制剤並びにこれを含有する化粧品及び食品
JPH09118612A (ja) * 1995-10-25 1997-05-06 Pola Chem Ind Inc 皮膚外用剤
WO1999062480A2 (fr) * 1998-05-29 1999-12-09 Parfums Christian Dior Utilisation d'au moins une saponine ou un sapogenol cosmetiquement acceptable, comme agent cosmetique destine a augmenter la quantite de collagene iv dans la jonction dermo-epidermique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322839A (en) * 1991-09-13 1994-06-21 Pentapharm Ag Protein fraction for cosmetic and dermatology care of the skin
JPH0853360A (ja) * 1994-06-10 1996-02-27 Suntory Ltd ヒスタミン遊離抑制剤並びにこれを含有する化粧品及び食品
JPH09118612A (ja) * 1995-10-25 1997-05-06 Pola Chem Ind Inc 皮膚外用剤
WO1999062480A2 (fr) * 1998-05-29 1999-12-09 Parfums Christian Dior Utilisation d'au moins une saponine ou un sapogenol cosmetiquement acceptable, comme agent cosmetique destine a augmenter la quantite de collagene iv dans la jonction dermo-epidermique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 122, no. 21, 22 May 1995, Columbus, Ohio, US; abstract no. 260997q, P. GOMATHINAYAGAM ET AL: "Seed protein pattern of cowpea (Vigna unguiculata L.) and its distant species" page 640; XP002137217 *
DATABASE WPI Week 199618, Derwent World Patents Index; AN 1996-175673, XP002137237, "Histamine release inhibitor, for cosmetics and food - comprises plant extracts e.g. Jambosa vulgaris" *
DATABASE WPI Week 199728, Derwent World Patents Index; AN 1997-306545, XP002137218, "External preparation for skin treatment - comprise dried and pulverised seeds of e.g. Vigna mungo" *
J. PLANT BIOCHEM. BIOTECHNOL., vol. 3, no. 2, 1994, pages 149 - 151 *
P. SIDDHURAJU ET AL: "Nutritional and chemical evaluation of raw seeds of the tribal pulse Vigna trilobata (L.) Verdc.", INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, vol. 43, 1992, pages 97 - 103, XP002137216 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101421230B (zh) * 2001-11-16 2011-04-13 辛根塔参与股份公司 新颖的苯基-炔丙基醚衍生物

Also Published As

Publication number Publication date
AU6276500A (en) 2001-02-13
FR2796839B1 (fr) 2003-05-23
FR2796839A1 (fr) 2001-02-02

Similar Documents

Publication Publication Date Title
DE69822546T2 (de) Kosmetische oder pharmazeutische Zusammensetzung, die ein Kulturmedium eines Mikroorganismus enthält
DE69735814T2 (de) Verwendung von komplexen in die herstellung von präparaten zur behandlung empfindlicher haut, verfahren zur herstellung und hypoallergenische präparate
DE102004045187B4 (de) Wirkstoffe zur Überführung von inaktivem TGFb-latent in aktiven TGFb und deren Verwendung in kosmetischen und pharmazeutischen Zusammensetzungen
DE102004028302B4 (de) Stimulierung der Synthese und der Aktivität einer Isoform der Lysyloxidase-ähnlichen LOXL zum Stimulieren der Bildung von elastischen Fasern
KR20200106893A (ko) 모링가 올레이페라 종자의 단백질 추출물의 미용 용도
DE69522103T2 (de) Verwendung des laminarins oder abgeleiteten oligosacchariden in der kosmetik oder dermatologie
JP2000169383A (ja) 抗アレルギー剤
DE69830397T2 (de) Verwendung eines adansonia-gattung extraktes
CN105726439B (zh) 金蝉花美白保湿药妆品及其制备方法
KR102367528B1 (ko) 해조류 추출물을 유효성분으로 포함하는 화장료 조성물
US20100040706A1 (en) Method of anti-ageing cosmetic care by stimulation of survivin expression
CN114502139B (zh) 富含2,5-二甲酰基呋喃的阿拉伯辣木种子提取物、其获得方法及其在化妆品组合物中的用途
KR20190063549A (ko) 대나무 발효물을 함유하는 화장료 조성물
WO2001007005A1 (fr) Utilisation d'une fraction de proteine de la graine de la plante vigna trilobata dans une composition cosmetique ou dermopharmaceutique
CN113631227A (zh) 抗老化剂、抗氧化剂、抗炎剂、及美白剂、以及化妆品
KR20030015654A (ko) 피부자극 및 염증완화 효과를 갖는 라스베리 잎 또는 열매추출물을 함유한 피부 외용제 조성물
KR100532633B1 (ko) 혼합 식물추출물을 함유한 항염증효과, 피부보호효과와피부탄력효과를 갖는 화장료 조성물
JP2004018492A (ja) ヒスタミン遊離抑制剤及び抗アレルギー剤並びに化粧料組成物
DE69803169T2 (de) Verwendung eines bambaraerdnuss-samenextraktes in einer kosmetischen zusamensetzung
DE60114940T2 (de) Verwendung eines Iridacea-Extrakts in einer Zusammensetzung für die Stimulierung der Immunabwehr
EP1140005B1 (fr) Utilisation d'un extrait d'une plante appartenant au genre cecropia
KR20030039726A (ko) 머위 추출물을 함유하는 항노화용 화장료 조성물
KR101207560B1 (ko) 빗죽이나무 추출물을 유효성분으로 함유하는 화장료 조성물
KR102233707B1 (ko) 천연 추출물 및 천연 가루를 포함하는 화장료 조성물
KR101207559B1 (ko) 윤노리나무 추출물을 유효성분으로 함유하는 화장료 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP